The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009
Open accessAbstract
Objective To assess the prevalence and correlates of antipsychotic polypharmacy (APP) across decades and regions. Methods Electronic PubMed/Google Scholar search for studies reporting on APP, published from 1970-05/2009. Median rates and interquartile ranges (IQR) were calculated and compared using non-parametric tests. Demographic and clinical variables were tested as correlates of APP in bivariate and meta-regression analyses. Results Across 147 studies (1,418,163 participants, 82.9% diagnosed with schizophrenia [IQR=42–100%]), the median APP rate was 19.6% (IQR=12.9–35.0%). Most common combinations included first-generation antipsychotics (FGAs)+second-generation antipsychotics (SGAs) (42.4%, IQR=0.0–71.4%) followed by FGAs+FGAs (19.6%, IQR=0.0–100%) and SGAs+SGAs (1.8%, IQR=0.0–28%). APP rates were not different between decades (1970–1979:28.8%, IQR=7.5–44%; 1980–1989:17.6%, IQR=10.8–38.2; 1990–1999:22.0%, IQR=11–40; 2000–2009:19.2% IQR=14.4–29.9, p=0.78), but between regions, being higher in Asia and Europe than North America, and in Asia than Oceania (p<0.001). APP increased numerically by 34% in North America from the 1980s 12.7%) to 2000s (17.0%) (p=0.94) and decreased significantly by 65% from 1980 (55.5%) to 2000 (19.2%) in Asia (p=0.03), with non-significant changes in Europe. APP was associated with inpatient status (p<0.001), use of FGAs (p<0.0001) and anticholinergics (<0.001), schizophrenia (p=0.01), less antidepressant use (p=0.02), greater LAIs use (p=0.04), shorter follow-up (p=0.001) and cross-sectional vs. longitudinal study design (p=0.03). In a meta-regression, inpatient status (p<0.0001), FGA use (0.046), and schizophrenia diagnosis (p=0.004) independently predicted APP (N=66, R2=0.44, p<0.0001). Conclusions APP is common with different rates and time trends by region over the last four decades. APP is associated with greater anticholinergic requirement, shorter observation time, greater illness severity and lower antidepressant use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Statistics for the Behavioral Sciences
Guitton, H., & Siegel, S. (1958) · Revue économique · doi:10.2307/3498751 · Cited by 35,245
(2000) · Cited by 9,198
Nonparametric statistics for the behavioral sciences
McGinn, L. C. (1957) · Journal of the Franklin Institute · doi:10.1016/0016-0032(57)90766-4 · Cited by 7,204
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Yatham, L., & Malhi, G. (2011) · Oxford University Press eBooks · doi:10.1093/med/9780199562305.001.0001 · Cited by 3,506
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Leucht, S., Wahlbeck, K., Hamann, J., & Kissling, W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13306-5 · Cited by 725
Correll, C. U., Rummel-Kluge, C., Corves, C., Kane, J. M., & Leucht, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn018 · Cited by 397
Self-citationSchizophrenia, neuroleptic medication and mortality
Joukamaa, M., Heliövaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.2.122 · Cited by 395
Povlsen, U. J., Norrng, U., Fog, R., & Gerlach, J. (1985) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1985.tb01268.x · Cited by 278
Waddington, J. L., Youssef, H. A., & Kinsella, A. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.173.4.325 · Cited by 267
Centorrino, F., Goren, J. L., Hennen, J., Salvatore, P., Kelleher, J. P., & Baldessarini, R. J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.700 · Cited by 253
Auquier, P., Lançon, C., Rouillon, F., Lader, M., & Holmes, C. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1325 · Cited by 249
Ganguly, R., Kotzan, J. A., Miller, L. S., Kennedy, K., & Martin, B. C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1013 · Cited by 227
Vinogradov, S., Fisher, M., Warm, H., Holland, C., Kirshner, M. A., & Pollock, B. G. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09010017 · Cited by 219
Safety and tolerability of antipsychotic polypharmacy
Gallego, J. A., Nielsen, J., De Hert, M., Kane, J. M., & Correll, C. U. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.683523 · Cited by 205
Self-citationPrior Antipsychotic Prescribing in Patients Currently Receiving Clozapine: A Case Note Review
Taylor, D. M., Young, C., & Paton, C. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0107 · Cited by 192
Clark, R. E., Bartels, S. J., Mellman, T. A., & Peacock, W. J. (2002) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006928 · Cited by 189
Faries, D., Ascher-Svanum, H., Zhu, B., Correll, C., & Kane, J. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-26 · Cited by 184
Self-citationCombination Antipsychotic Therapy in Clinical Practice
Tapp, A., Wood, A. E., Secrest, L., Erdmann, J., Cubberley, L., & Kilzieh, N. (2003) · Psychiatric Services · doi:10.1176/appi.ps.54.1.55 · Cited by 181
Effectiveness of Switching From Antipsychotic Polypharmacy to Monotherapy
Essock, S. M., Schooler, N. R., Stroup, T. S., McEvoy, J. P., Rojas, I., Jackson, C., Covell, N. H., & The Schizophrenia Trials Network (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10060908 · Cited by 179
McIntyre, R. S., & Jerrell, J. M. (2008) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.162.10.929 · Cited by 178
Clinical Management of Clozapine Patients in Relation to Efficacy and Side-Effects
Naber, D., Holzbach, R., Perro, C., & Hippius, H. (1992) · British Journal of Psychiatry · doi:10.1192/s0007125000296931 · Cited by 178
Covell, N. H., Jackson, C. T., Evans, A. C., & Essock, S. M. (2002) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006920 · Cited by 172
Heterogeneity of violence in schizophrenia and implications for long-term treatment
Volavka, J., & Citrome, L. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01797.x · Cited by 160
Élie, D., Poirier, M., Chianetta, J. M., Durand, M., Gregoire, C. A., & Grignon, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108100777 · Cited by 153
Does the Addition of a Second Antipsychotic Drug Improve Clozapine Treatment?
Barbui, C., Signoretti, A., Mule, S., Boso, M., & Cipriani, A. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn030 · Cited by 153
Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial
Chakos, M., Glick, I. D., Miller, A. L., Hamner, M. B., Miller, D. D., Patel, J. K., Tapp, A. M., Keefe, R. S. E., & Rosenheck, R. A. (2006) · Psychiatric Services · doi:10.1176/appi.ps.57.8.1094 · Cited by 147
Antipsychotic medication and cognitive function in schizophrenia
Hori, H., Noguchi, H., Hashimoto, R., Nakabayashi, T., Omori, M., Takahashi, S., Tsukue, R., Anami, K., Hirabayashi, N., Harada, S., et al. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.05.004 · Cited by 147
Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change
Chong, M., Tan, C. H., Fujii, S., Yang, S., UNGVARI, G. S., Si, T., Chung, E. K., Sim, K., Tsang, H., & Shinfuku, N. (2003) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2004.01194.x · Cited by 146
Antipsychotic Polypharmacy, Part 1: Therapeutic Option or Dirty Little Secret?
Stahl, S. M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0701 · Cited by 144
Sim, K., Su, A., Fujii, S., Yang, S., Chong, M., Ungvari, G. S., Si, T., Chung, E. K., Tsang, H., Chan, Y. H., et al. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02102.x · Cited by 142
Results of phase 3 of the CATIE schizophrenia trial
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Thomas, S., Swartz, M. S., Keefe, R. S. E., Miller, A. L., Rosenheck, R. A., & Hsiao, J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.10.011 · Cited by 141
When Symptoms Persist: Clozapine Augmentation Strategies
Buckley, P., Miller, A. L., Olsen, J., Garver, D., Miller, D. D., & Csernansky, J. G. (2001) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006901 · Cited by 139
Survey of neuroleptic prescribing in residents of nursing homes in Glasgow: Table 1
McGrath, A., & Jackson, G. A. (1996) · BMJ · doi:10.1136/bmj.312.7031.611 · Cited by 132
Polypharmacy and excessive dosing: Psychiatrists' perceptions of antipsychotic drug prescription
Ito, H., Koyama, A., & Higuchi, T. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.187.3.243 · Cited by 130
Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia
Suzuki, T., Uchida, H., Tanaka, K. F., Nomura, K., Takano, H., Tanabe, A., Watanabe, K., Yagi, G., & Kashima, H. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703004012 · Cited by 126
Patterns and Quality of Treatment for Patients With Schizophrenia in Routine Psychiatric Practice
West, J. C., Wilk, J. E., Olfson, M., Rae, D. S., Marcus, S. C., Narrow, W. E., Pincus, H. A., & Regier, D. A. (2005) · Psychiatric Services · doi:10.1176/appi.ps.56.3.283 · Cited by 117
Antipsychotic medication coprescribing in a large state hospital system
Jaffe, A. B., & Levine, J. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.783 · Cited by 111
Polypharmacy in Patients With Schizophrenia
McCue, R. E., Waheed, R., & Urcuyo, L. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0902 · Cited by 110
Harrington, M., Lelliott, P. T., Paton, C., et al. (2002) · Psychiatric Bulletin · doi:10.1192/pb.26.11.414 · Cited by 106
Inpatient Antipsychotic Drug Use in 1998, 1993, and 1989
Centorrino, F., Eakin, M., Bahk, W., Kelleher, J. P., Gören, J. L., Salvatore, P., Egli, S., & Baldessarini, R. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1932 · Cited by 105
LESLIE, D. L., & Rosenheck, R. A. (2001) · Medical Care · doi:10.1097/00005650-200109000-00003 · Cited by 105
Obesity and Metabolic Syndrome in a Psychiatric Rehabilitation Service
Tirupati, S., & Chua, L.-E. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701392841 · Cited by 100
Kreyenbuhl, J. A., Valenstein, M. M., McCarthy, J. F., Ganoczy, D. A., & Blow, F. C. (2007) · Psychiatric Services · doi:10.1176/appi.ps.58.4.489 · Cited by 99
Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior
Correll, C. U., Shaikh, L., Gallego, J. A., Nachbar, J., Olshanskiy, V., Kishimoto, T., & Kane, J. M. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.02.016 · Cited by 97
Self-citationLelliott, P. T., Paton, C., Harrington, M., Konsolaki, M., Sensky, T., & Okocha, C. I. (2002) · Psychiatric Bulletin · doi:10.1192/pb.26.11.411 · Cited by 97
Wang, P. S., West, J. C., Tanielian, T., & Pincus, H. A. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033465 · Cited by 92
Barbui, C., Nos, M., Mazzi, M. A., Thornicroft, G., Schene, A. H., Becker, T. M., Bindman, J. P., Leese, M., Helm, H., Koeter, M. W. J., et al. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000224785.68040.43 · Cited by 91
Gilmer, T., Dolder, C. R., Folsom, D. P., Mastin, W., & Jeste, D. V. (2007) · Psychiatric Services · doi:10.1176/ps.2007.58.7.1007 · Cited by 88
Patterns of Antipsychotic and Anticholinergic Prescribing for Hospital Inpatients
Paton, C., Duffett, R., Harrington, M., Lelliott, P. T., Okocha, C. I., & Sensky, T. (2003) · Journal of Psychopharmacology · doi:10.1177/0269881103017002012 · Cited by 87
Psychotropics among the home‐dwelling elderly—increasing trends
Linjakumpu, T., Hartikainen, S. A., Klaukka, T., Koponen, H., Kivelä, S., & Isoaho, R. E. (2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.712 · Cited by 87
Morrato, E. H., Dodd, S. L., Oderda, G. M., Haxby, D. G., Allen, R. R., & Valuck, R. J. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.002 · Cited by 86
Long-term combination antipsychotic treatment in VA patients with schizophrenia
Kreyenbuhl, J. A., Valenstein, M. M., McCarthy, J. F., Ganoczy, D. A., & Blow, F. C. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.02.023 · Cited by 84
Broekema, W. J., de Groot, I. W., & van Harten, P. N. (2007) · Pharmacy World & Science · doi:10.1007/s11096-006-9063-1 · Cited by 81
Adverse events in children and adolescents treated with antipsychotic medications
Jerrell, J. M., & McIntyre, R. S. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.932 · Cited by 80
Benefits and Risks of Antipsychotic Polypharmacy
Tranulis, C., Skalli, L., Lalonde, P., Nicole, L., & Stip, É. (2008) · Drug Safety · doi:10.2165/00002018-200831010-00002 · Cited by 78
Fourrier, A., Gasquet, I., Allicar, M. P., Bouhassira, M., Lepine, J. P., & Bégaud, B. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00108.x · Cited by 77
Drug Prescribing for Schizophrenic Out-patients on Depot Injections
Johnson, D. A. W., & Wright, N. F. (1990) · The British Journal of Psychiatry · doi:10.1192/bjp.156.6.827 · Cited by 74
Benzodiazepines for neuroleptic-induced acute akathisia
Lima, A. R., Soares‐Weiser, K., Bacaltchuk, J., & Barnes, T. R. E. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001950 · Cited by 73
Testing for diabetes in hospitalised patients prescribed antipsychotic drugs
Taylor, D. M., Young, C., Esop, R., Paton, C., & Walwyn, R. E. A. (2004) · The British Journal of Psychiatry · doi:10.1192/bjp.185.2.152 · Cited by 73
Ahn, J., McCombs, J. S., Jung, C., Croudace, T. J., McDonnell, D., Ascher‐Svanum, H., Edgell, E. T., & Shi, L. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00214.x · Cited by 73
Carnahan, R. M., Lund, B. C., Perry, P. J., & Chrischilles, E. A. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00589.x · Cited by 71
An Audit of Outpatient Antipsychotic Usage in the Three Health Sectors of Auckland, New Zealand
Humberstone, V., Wheeler, A., & Lambert, T. J. R. (2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2004.01340.x · Cited by 69
Antipsychotic Use in Australia: The Patients' Perspective
Castle, D. J., Castle, D. J., Morgan, V. A., & Jablensky, A. V. (2002) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2002.01037.x · Cited by 68
Combination treatment in bipolar disorder: a review of controlled trials
Zarate, C. A., & Quiroz, J. A. (2003) · Bipolar Disorders · doi:10.1034/j.1399-5618.2003.00034.x · Cited by 66
Rosenheck, R., LESLIE, D. L., & Sernyak, M. J. (2001) · Medical Care · doi:10.1097/00005650-200103000-00010 · Cited by 65
Evaluation of Antipsychotic and Concomitant Medication Use Patterns in Patients With Schizophrenia
Williams, C. L., Johnstone, B. M., Kesterson, J. G., Javor, K. A., & Schmetzer, A. D. (1999) · Medical Care · doi:10.1097/00005650-199904001-00011 · Cited by 65
Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay
Baldessarini, R. J., Kando, J. C., & Centorrino, F. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.7.1038 · Cited by 59
Clozapine in the treatment of 121 out-patients
Leppig, M., Bosch, B., Naber, D., et al. (1989) · Psychopharmacology · doi:10.1007/bf00442565 · Cited by 58
Polypharmacy With Second-Generation Antipsychotics: A Review of Evidence
Pandurangi, A. K., & Dalkiliç, A. (2008) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000341890.05383.45 · Cited by 57
Validation of Polypharmacy Process Measures in Inpatient Schizophrenia Care
Janssen, B., Weinmann, S., Berger, T., & Gäebel, W. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007117 · Cited by 57
Multiple Antipsychotic Medication Prescribing Patterns
Schumacher, J. E., Makela, E. H., & Griffin, H. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c420 · Cited by 54
Prescribing for Inpatients with Schizophrenia: An International Multi-Center Comparative Study
Bitter, I., Chou, J. C.-Y., Ungvari, G. S., Tang, W. K., Xiang, Z., Iwanami, A., & Gaszner, P. (2003) · Pharmacopsychiatry · doi:10.1055/s-2003-41199 · Cited by 53
Xiang, Y., Weng, Y.-Z., Leung, C. M., Tang, W. K., & Ungvari, G. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-970062 · Cited by 53
Kogut, S. J., Yam, F. K., & Dufresne, R. L. (2005) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2005.11.1.17 · Cited by 50
Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia
Kreyenbuhl, J. A., Marcus, S. C., West, J. C., Wilk, J. E., & Olfson, M. (2007) · Psychiatric Services · doi:10.1176/appi.ps.58.7.983 · Cited by 47
Edlinger, M., Hausmann, A., Kemmler, G., Kurz, M., Kurzthaler, I., Walch, T., Walpoth, M., & Fleischhacker, W. W. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.01.015 · Cited by 44
Comparing the Use and Discontinuation of Antipsychotics in Clinical Practice
Taylor, M., Shajahan, P. M., & Lawrie, S. M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0210 · Cited by 43
Loosbrock, D. L., Zhao, Z., Johnstone, B. M., & Morris, L. S. (2003) · PubMed · Cited by 41
Pharmacological treatment of ambulatory schizophrenic patients in Belgium.
Hanssens, L. S., Hert, M. A. F. D., Wampers, M., Jy, R., & Peuskens, J. (2006) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-2-11 · Cited by 38
Hospital use of antipsychotic drugs: polytherapy
Centorrino, F., Cincotta, S. L., Talamo, A., Fogarty, K. V., Guzzetta, F., Saadeh, M., Salvatore, P., & Baldessarini, R. J. (2007) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2007.08.002 · Cited by 38
Patterns of Antipsychotic Utilization in a Tertiary Care Psychiatric Institution
Procyshyn, R. M., & Thompson, B. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-815469 · Cited by 38
Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia
Kreyenbuhl, J. A., Marcus, S. C., West, J. C., Wilk, J. E., & Olfson, M. (2007) · Psychiatric Services · doi:10.1176/ps.2007.58.7.983 · Cited by 38
Economic reforms and the acute inpatient care of patients with schizophrenia: the Chinese experience
Phillips, M. R., Lu, S., & Wang, R. W. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.9.1228 · Cited by 35
Datapoints: Antipsychotic Polypharmacy in the Ambulatory Care Setting, 1993-2000
Botts, S. R., Hines, H., & Littrell, R. A. (2003) · Psychiatric Services · doi:10.1176/appi.ps.54.8.1086 · Cited by 35
Anticholinergics for neuroleptic-induced acute akathisia
Lima, A., Weiser, K., Bacaltchuk, J., & Barnes, T. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003727.pub2 · Cited by 35
General Practice Patients on Long-Term Psychotropic Drugs
Catalán, J., Gath, D. H., Bond, A., Edmonds, G., Martin, P., & Ennis, J. (1988) · The British Journal of Psychiatry · doi:10.1192/bjp.152.3.399 · Cited by 34
Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey
The National Mental Health Project Working Group, Magliano, L., Fiorillo, A., Guarneri, M., Marasco, C., Rosa, C. D., Malangone, C., & Maj, M. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0803-7 · Cited by 34
Tomasi, R., de Girolamo, G., Santone, G., Picardi, A., Micciolo, R., Semisa, D., Fava, S., & the PROGRES Group (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00657.x · Cited by 33
Suzuki, T., Uchida, H., Watanabe, K., Yagi, G., & Kashima, H. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.11.006 · Cited by 33
Linden, M., Scheel, T., & Eich, F. X. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.574 · Cited by 31
Anticholinergic Use in Children and Adolescents After Initiation of Antipsychotic Therapy
Hong, I. S., & Bishop, J. R. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m643 · Cited by 31
Chong, S., Ravichandran, N., Poon, L. Y., Soo, K.-L., & Verma, S. (2006) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v35n7p457 · Cited by 30
A survey of psychotropic medication in mental retardation facilities.
Tu, J. (1979) · PubMed · Cited by 28
Megna, J. L., Kunwar, A., MAHLOTRA, K., Sauro, M. D., Devitt, P. J., & Rashid, A. (2007) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000265773.03756.3e · Cited by 28
How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs
Valuck, R. J., Morrato, E. H., Dodd, S. L., Oderda, G. M., Haxby, D. G., Allen, R. R., & on behalf of the Medicaid pharmacotherapy research Consortium (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x233214 · Cited by 27
Rosholm, J.-U., Hallas, J., & Gram, L. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04300.x · Cited by 27
Millier, A., Sarlon, E., Azorin, J., Boyer, L., Aballéa, S., Auquier, P., & Toumi, M. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-24 · Cited by 27
Antipsychotic Polypharmacy in Patients With Schizophrenia in a Brief Hospitalization Unit
Lerma-Carrillo, I., Brühlmann, S. D. P., Leonor, M., Pascual-Pinazo, F., Molina, J. D. D., & Baca‐García, E. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31815cba78 · Cited by 26
Connolly, A., Rogers, P. C., & Taylor, D. M. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107065899 · Cited by 24
Trends in Antipsychotic Prescribing in Schizophrenia in Auckland
Wheeler, A., Humberstone, V., & Robinson, G. (2006) · Australasian Psychiatry · doi:10.1080/j.1440-1665.2006.02273.x · Cited by 23
Xiang, Y., Weng, Y.-Z., Leung, C. M., Tang, W. K., & Ungvari, G. S. (2008) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp46245 · Cited by 23
Ungvari, G. S., Chung, Y. G., Yip, K. C., Fung‐Shing, N., Kwong, T. W., & Chiu, H. F. K. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01668.x · Cited by 20
Bingefors, K., Isacson, D. G. L., & Lindström, E. (2003) · Nordic Journal of Psychiatry · doi:10.1080/08039480307280 · Cited by 18
Ballerini, A., Boccalon, R. M., Boncompagni, G., CASACCHIA, M., Margari, F., Minervini, L., Righi, R., Russo, F., Salteri, A., Frediani, S., et al. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-29 · Cited by 18
Polypharmazie in der Behandlung der Schizophrenie
Messer, T., Tiltscher, C., & Schmauß, M. (2006) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-2005-915576 · Cited by 18
Castberg, I., & Spigset, O. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31818622c4 · Cited by 16
Molina, J. D. D., Lerma-Carrillo, I., Leonor, M., Pascual, F., Blasco-Fontecilla, H., González‐Parra, S., Lopez-Munoz, F. J., & Álamo, C. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181672213 · Cited by 16
Polypharmazie in der Behandlung der Schizophrenie
Messer, T., Tiltscher, C., & Schmauß, M. (2009) · Springer eBooks · doi:10.1007/978-3-211-79826-3_2 · Cited by 15
Antipsychotic Drug Doses and Adjunctive Drugs in the Outpatient Treatment of Schizophrenia
Galletly, C. A., & Tsourtos, G. (1997) · Annals of Clinical Psychiatry · doi:10.3109/10401239709147777 · Cited by 15
Schorr, S. G., LOONEN, A. J. M., Brouwers, J. R. B. J., & Taxis, K. (2008) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp46146 · Cited by 13
Barbui, C., Nosè, M., Mazzi, M. A., Bindman, J. P., Leese, M., Schene, A. H., Becker, T. M., Angermeyer, M. C., Koeter, M. W. J., Gray, R. J., et al. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000185022.48279.db · Cited by 13
Antipsychotic use in patients with schizophrenia treated in private psychiatry
Valterio, C. (2005) · Swiss Medical Weekly · doi:10.4414/smw.2005.10727 · Cited by 13
Renkel, S., & Rasmussen, K. B. (2006) · Nordic Journal of Psychiatry · doi:10.1080/08039480600583662 · Cited by 12
Lass, J., Männik, A., & Bell, J. S. (2008) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2008.00900.x · Cited by 10
Soni, S. D., Sampath, G., Shah, A., & Krska, J. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb10318.x · Cited by 8
Andersen, S. E., Johansson, M., & Manniche, C. (2008) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2008.00233.x · Cited by 6
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Tiihonen, J., Taipale, H., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tanskanen, A. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.4320 · Cited by 297
Self-citationThe acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses
Haddad, P. M., & Correll, C. U. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125318781475 · Cited by 259
Self-citationCorrell, C. U., Rubio, J. M., Inczedy-Farkas, G., Birnbaum, M. L., Kane, J. M., & Leucht, S. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0624 · Cited by 214
Self-citationBaandrup, L. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13384 · Cited by 79
Metadata
- Authors
- Gallego, J. A., Bonetti, J., Zhang, J., Kane, J. M., & Correll, C. U.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 138
- Issue
- 1
- Pages
- 18-28
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2013615650
- Cited by
- 332
- References
- 119
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.